Drug intelligence / Profile preview

iboxamase

Development stage: Preclinical
Lead developer: Theriva Biologics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

Iboxamase (P2G) is an oral enzyme biologic developed by Synthetic Biologics. It is a component of the drug candidate SYN-004, which is designed to prevent *Clostridioides difficile* infection. Iboxamase achieves this by inactivating intravenous antibiotics within the gastrointestinal tract, thereby preserving the gut microbiome.

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on iboxamase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iboxamase.

Explore the full profile